Literature DB >> 10973444

T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune).

R B Moss1, W Giermakowska, M R Wallace, J Savary, F Jensen, D J Carlo.   

Abstract

The discovery of multiple subtypes of human immunodeficiency virus type 1 (HIV-1) worldwide has created new challenges for the development of both therapeutic and preventive AIDS vaccines. We examined T-helper proliferative responses to HIV-1 clade A, B, C, G, and E whole-killed virus and to HIV-1 clade G and B core (p24) antigens in HIV-1-infected subjects taking potent antiviral drugs who received HIV immunogen (Remune) therapeutic vaccination. Subjects who were immunized mounted strong proliferative responses to both whole virus and core antigens of the different clades. These results suggest that a whole-killed immunogen may have broad applications as a therapeutic as well as a preventive vaccine in the current multiclade HIV-1 pandemic.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973444      PMCID: PMC95945          DOI: 10.1128/CDLI.7.5.724-727.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  27 in total

Review 1.  Insights into HIV-specific immune function: implications for therapy and prevention in the new millennium.

Authors:  R B Moss; F C Jensen; D J Carlo
Journal:  Clin Immunol       Date:  2000-05       Impact factor: 3.969

2.  Investigations of the use of beta-propiolactone in virus inactivation.

Authors:  G A LOGRIPPO
Journal:  Ann N Y Acad Sci       Date:  1960-01-13       Impact factor: 5.691

3.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

4.  Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography.

Authors:  S P Richieri; R Bartholomew; R C Aloia; J Savary; R Gore; J Holt; F Ferre; R Musil; H R Tian; R Trauger; P Lowry; F Jensen; D J Carlo; R Z Maigetter; C P Prior
Journal:  Vaccine       Date:  1998 Jan-Feb       Impact factor: 3.641

5.  HIV-1-Specific Functional Immune Measurements as Markers of Disease Progression.

Authors:  R.B. Moss; S.P. Richieri; F. Ferre; A.E. Daigle; R. Trauger; G. Theofan; W. Giermakowska; P. Lanza; S. Brostoff; D.J. Carlo; F.C. Jensen
Journal:  J Biomed Sci       Date:  1997 Jul-Aug       Impact factor: 8.410

6.  Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons.

Authors:  M Vesanen; C E Stevens; P E Taylor; P Rubinstein; K Saksela
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.

Authors:  J B Angel; A Kumar; K Parato; L G Filion; F Diaz-Mitoma; P Daftarian; B Pham; E Sun; J M Leonard; D W Cameron
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

8.  Primary subtype C HIV-1 infection in Harare, Zimbabwe.

Authors:  P C Tien; T Chiu; A Latif; S Ray; M Batra; C H Contag; L Zejena; M Mbizvo; E L Delwart; J I Mullins; D A Katzenstein
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-02-01

9.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.

Authors:  G Pantaleo; S Menzo; M Vaccarezza; C Graziosi; O J Cohen; J F Demarest; D Montefiori; J M Orenstein; C Fox; L K Schrager
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

10.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

View more
  3 in total

1.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

Review 2.  Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis.

Authors:  Diana Finzi; Susan F Plaeger; Carl W Dieffenbach
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Immunotherapy with an HIV-DNA Vaccine in Children and Adults.

Authors:  Paolo Palma; Lindvi Gudmundsdotter; Andrea Finocchi; Lars E Eriksson; Nadia Mora; Veronica Santilli; Angela Aquilani; Emma C Manno; Paola Zangari; Maria Luisa Romiti; Carla Montesano; Alba Grifoni; Andreas Brave; Karl Ljungberg; Pontus Blomberg; Stefania Bernardi; Eric Sandström; Bo Hejdeman; Paolo Rossi; Britta Wahren
Journal:  Vaccines (Basel)       Date:  2014-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.